SCHEMBL5686134

SCHEMBL5686134

CCCN1CCN(CCOc2ccc(Nc3ncc(C(=O)Nc4c(C)cccc4C)c(Oc4ccc(CC(=O)N(CC)CC)cc4OC)n3)cc2F)CC1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LCK P06239 6/20 0.47
BTK Q06187 4/20 0.47
TNK2 Q07912 3/20 0.47
JAK3 P52333 2/20 0.47
KDR P35968 5/20 0.41
SRC P12931 4/20 0.41
MAPK14 Q16539 2/20 0.41
SIK1 P57059 2/20 0.40
SIK2 Q9H0K1 2/20 0.40
SIK3 Q9Y2K2 2/20 0.40
MET P08581 6/20 0.39
EGFR P00533 2/20 0.38
ITK Q08881 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5686829 0.95 LCK (0.47) LCKBTKTNK2JAK3KDR
SCHEMBL4494368 0.94 LCK (0.45) LCKBTKTNK2JAK3KDR
SCHEMBL4488873 0.93 KDR (0.49) LCKBTKTNK2JAK3KDR
SCHEMBL4496870 0.92 LCK (0.49) LCKBTKTNK2JAK3KDR
SCHEMBL5689088 0.91 LCK (0.48) LCKBTKTNK2JAK3KDR
SCHEMBL5686467 0.90 LCK (0.47) LCKBTKTNK2JAK3KDR
SCHEMBL5686245 0.90 LCK (0.45) LCKBTKTNK2JAK3KDR
SCHEMBL5686310 0.89 LCK (0.55) LCKBTKTNK2JAK3KDR
SCHEMBL4499611 0.89 LCK (0.45) LCKBTKTNK2JAK3KDR
SCHEMBL4496477 0.88 LCK (0.48) LCKBTKTNK2JAK3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed